How does XLSZ's PE Ratio compare to its peers?

XLSZ is good value based on its Price-To-Earnings Ratio (6.8x) compared to the peer average (10.7x).

How does XLSZ's PE Ratio compare vs other companies in the European Life Sciences Industry?

XLSZ is good value based on its Price-To-Earnings Ratio (6.8x) compared to the European Life Sciences industry average (37.4x).

What is XLSZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate XLSZ's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of XLSZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

XLSZ (CHF25.5) is trading below our estimate of [[fair value]] (CHF30.85)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

XLSZ Stock Overview

Focuses on the development and commercialization of technologies in the life sciences sector. More details

XLSZ fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	4/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 17.4% below our estimate of its fair value

Earnings grew by 31.7% over the past year

Risk Analysis

Shareholders have been diluted in the past year

Volatile share price over the past 3 months compared to the UK market

Large one-off items impacting financial results

Does not have meaningful revenue (CHF990K)

My Notes

Capture your thoughts, links and company narrative

Xlife Sciences AG Competitors

hVIVO

AIM:HVO

UK£133.7m

Ergomed

AIM:ERGO

UK£701.1m

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Bioventix

AIM:BVXP

UK£173.6m

Price History & Performance

Summary of share price highs, lows and changes for Xlife Sciences
Historical stock prices
Current Share Price	CHF 25.50
52 Week High	CHF 43.40
52 Week Low	CHF 23.40
Beta	0.54
1 Month Change	-12.52%
3 Month Change	-16.67%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-40.56%

Recent updates

Shareholder Returns

	XLSZ	GB Life Sciences	GB Market
7D	-2.7%	-5.9%	-2.6%
1Y	n/a	-26.2%	2.4%

Return vs Industry: Insufficient data to determine how XLSZ performed against the UK Life Sciences industry.

Return vs Market: Insufficient data to determine how XLSZ performed against the UK Market.

Price Volatility

Is XLSZ's price volatile compared to industry and market?
XLSZ volatility
XLSZ Average Weekly Movement	9.9%
Life Sciences Industry Average Movement	7.2%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: XLSZ's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: XLSZ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2019	17	Oliver Baumann	www.xlifesciences.ch

Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector. The company’s project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and early identification kidney diseases.

Xlife Sciences AG Fundamentals Summary

How do Xlife Sciences's earnings and revenue compare to its market cap?
XLSZ fundamental statistics
Market cap	CHF 143.54m
Earnings (TTM)	CHF 21.24m
Revenue (TTM)	CHF 990.27k

6.8x

P/E Ratio

145.0x

P/S Ratio

Is XLSZ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XLSZ income statement (TTM)
Revenue	CHF 990.27k
Cost of Revenue	CHF 450.93k
Gross Profit	CHF 539.34k
Other Expenses	-CHF 20.70m
Earnings	CHF 21.24m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Apr 25, 2025

Earnings per share (EPS)	3.70
Gross Margin	54.46%
Net Profit Margin	2,144.50%
Debt/Equity Ratio	15.0%

How did XLSZ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 23:27
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xlife Sciences AG is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Daniel Jelovcan	Stifel, Equities Research
Ulrich Huwald	Warburg Research GmbH

Xlife Sciences BATS-CHIXE:XLSZ Stock Report